Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Future trends in antiarrhythmic therapy.

P Coumel1

  • 1Hôpital Lariboisière, Paris, France.

Journal of Cardiovascular Pharmacology
|January 1, 1991
PubMed
Summary
This summary is machine-generated.

Current antiarrhythmic drug therapy shows unexpected outcomes, with some drugs worsening patient conditions. Beta-blockers, however, demonstrate efficacy in preventing sudden cardiac death, even in heart failure patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[From provocation tests to clinical practice: invasive and non-invasive electrophysiology].

Archives des maladies du coeur et des vaisseaux·2003
Same author

[Indications for implantable automatic defibrillators: critical analysis].

Archives des maladies du coeur et des vaisseaux·2003
Same author

Safety of a controlled-release flecainide acetate formulation in the prevention of paroxysmal atrial fibrillation in outpatients.

Annales de cardiologie et d'angeiologie·2003
Same author

Atrial fibrillation: one more sporting inconvenience?

European heart journal·2002
Same author

Learning from mistakes: the case of clinical electrophysiology: a perspective on evidence-based rhythmology.

Circulation·2001
Same author

Sotalol: a fool's deal?

European heart journal·2001
Same journal

Integration of Mendelian Randomization and FAERS Database Analysis Reveals the Association Between Ergotamine and Aortic and Mitral Valve Diseases.

Journal of cardiovascular pharmacology·2026
Same journal

A Comprehensive Review of PCSK9 Inhibitor Therapy.

Journal of cardiovascular pharmacology·2026
Same journal

SGLT2 Inhibitors and Progression of Chronic Kidney Disease in Patients with Elevated Lipoprotein(a): A Real-World Cohort Study.

Journal of cardiovascular pharmacology·2026
Same journal

Aspirin in primary prevention: a case for selective use.

Journal of cardiovascular pharmacology·2026
Same journal

GLP-1 Gene Therapy Trial for Obesity and Type 2 Diabetes: Towards a New Paradigm for Chronic Disease Treatment.

Journal of cardiovascular pharmacology·2026
Same journal

Expert Opinion: Restrictions, Precautions, or Normalcy? Defining Everyday Risk in Patients Treated With IL-1 Blockers for Recurrent Pericarditis.

Journal of cardiovascular pharmacology·2026
See all related articles

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • Antiarrhythmic therapy faces challenges due to conflicting results from major sudden death prevention trials.
  • Established antiarrhythmic drugs may not improve outcomes and can potentially harm patients.

Purpose of the Study:

  • To re-evaluate the efficacy and mechanisms of antiarrhythmic drugs in light of recent trial data.
  • To explore discrepancies between drugs effective for routine arrhythmias and those preventing sudden cardiac death.

Main Methods:

  • Analysis of large-scale therapeutic trials on sudden death prevention.
  • Review of established pharmacological principles versus observed clinical outcomes.
  • Consideration of the role of adrenergic stimulation in arrhythmia severity.

Related Experiment Videos

Main Results:

  • Drugs with known antiarrhythmic properties showed no benefit and sometimes adverse effects.
  • Beta-blockers proved effective in preventing death, particularly in heart failure subgroups.
  • Calcium antagonists and amiodarone exhibited complex effects not easily explained by simplistic models.

Conclusions:

  • Current approaches to understanding arrhythmia mechanisms and drug effects may be overly simplistic.
  • The determinants of routine arrhythmias may differ from those causing sudden death.
  • Revisiting drug evaluation methods and key arrhythmia parameters is crucial for effective antiarrhythmic therapy.